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Vitamin B1 Analog Benfotiamine Prevents Diabetes-Induced
Diastolic Dysfunction and Heart Failure Through Akt/Pim-1–
Mediated Survival Pathway
Rajesh G. Katare, MD, Andrea Caporali, PhD, Atsuhiko Oikawa, PhD, Marco Meloni, PhD,
Costanza Emanueli, PhD, and Paolo Madeddu, MD
Experimental Cardiovascular Medicine, Bristol Heart Institute, University of Bristol, United
Kingdom.
Abstract
Background—The increasing incidence of diabetes mellitus will result in a new epidemic of
heart failure unless novel treatments able to halt diabetic cardiomyopathy early in its course are
introduced. This study aimed to determine whether the activity of the Akt/Pim-1 signaling
pathway is altered at critical stages of diabetic cardiomyopathy and whether supplementation with
vitamin B1 analog benfotiamine (BFT) helps to sustain the above prosurvival mechanism, thereby
preserving cardiomyocyte viability and function.
Methods and Results—Untreated streptozotocin-induced type 1 or leptin-receptor mutant type
2 diabetic mice showed diastolic dysfunction evolving to contractile impairment and cardiac
dilatation and failure. BFT (70 mg/kg−1/d−1) improved diastolic and systolic function and
prevented left ventricular end-diastolic pressure increase and chamber dilatation in both diabetic
models. Moreover, BFT improved cardiac perfusion and reduced cardiomyocyte apoptosis and
interstitial fibrosis. In hearts of untreated diabetic mice, the expression and activity of Akt/Pim-1
signaling declined along with O-N-acetylglucosamine modification of Akt, inhibition of pentose
phosphate pathway, activation of oxidative stress, and accumulation of glycation end products.
Furthermore, diabetes reduced signal transducer and activator of transcription 3 phosphorylation
independently of Akt. BFT inhibited these effects of diabetes mellitus, thereby conferring
cardiomyocytes with improved resistance to high glucose-induced damage. The
phosphoinositide-3-kinase inhibitor LY294002 and dominant-negative Akt inhibited antiapoptotic
action of BFT and Pim-1 upregulation in high glucose-challenged cardiomyocytes.
Conclusions—These results show that BFT protects from diabetes mellitus-induced cardiac
dysfunction through pleiotropic mechanisms, culminating in the activation of prosurvival
signaling pathway. Thus, BFT merits attention for application in clinical practice.
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Diabetes mellitus (DM) is a potent and prevalent risk factor for heart failure independent of
coronary artery disease or hypertension.1 Diabetic cardiomyopathy has an insidious onset
and remains, therefore, undiagnosed and untreated in a large number of patients.
Furthermore, recent studies have shown evidence of diastolic dysfunction in up to 75% of
young, asymptomatic patients with type 1 or type 2 DM.2 The association of diastolic
dysfunction and microangiopathy synergistically increases the risk of heart failure, thus
pointing out the urgent need of early mechanistic treatment.3,4
A variety of molecular alterations have been associated with diabetic cardiomyopathy,
including defects in calcium homeostasis5 and substrate metabolism,6 accumulation of
advanced glycation end products (AGE),7 activation of the hexosamine pathway,8 and
oxidative stress leading to cardiomyocyte apoptosis.9 However, early stage mechanisms
remain mostly unknown.
The pivotal role of the phosphoinositide-3-kinase (PI3K)/Akt/proviral integration site for the
Moloney murine leukemia virus-1 (Pim-1) signaling pathway in the control of cardiac
contractile function and cardiomyocyte growth and survival is well established.10-12 Of
note, the hearts of mice with long-standing DM show decreased levels of activated Akt,13
and intriguingly, signal transducer and activator of transcription 3 (STAT3 [an upstream
modulator of Pim-1])-deficient mice spontaneously develop a form of dilated
cardiomyopathy similar to that occurring in diabetic mice.14 However, to the best of our
knowledge, no information exists on whether altered glucose metabolism may dampen the
activity of the STAT3/Akt/Pim-1 trio from early phases of cardiomyopathy and whether
pharmacological manipulation of such kinases could help to halt DM-induced cardiac
damage.
The conversion of glucose to pentose is hampered in DM because of the inhibition of pivotal
enzymes of the pentose phosphate pathway, such as transketolase and glucose-6-phosphate
dehydrogenase, resulting in depletion of reducing agents and accumulation of glycolysis end
products.15,16 Inhibition of transketolase activity was ascribed to deficit of its coenzyme
thiamine. This situation is further aggravated by the fact that increased reactive oxygen
species induces compensatory activation of the DNA-repairing enzyme poly(ADP-ribose)
polymerase, which in turn inhibits the activity of GAPDH, a crucial enzyme of glycolysis.
Intermediate metabolites of glycolysis consequently are forced down to alternative
pathways, including AGE formation and hexosamine pathway, which are responsible for
protein modification and inactivation and cardiovascular damage.17,18
The aim of this study was 2-fold: (1) to verify whether high glucose might alter STAT3/Akt/
Pim-1 expression and activity from early stages of cardiomyopathy and (2) to determine
whether benfotiamine (BFT) supplementation can sustain prosurvival signaling and prevent
cardiac dysfunction in DM. The rationale of BFT supplementation is to correct thiamine
deficit and thereby provide a shunt for glucose through the pentose pathway. Results of this
study show the chronological alterations in the prosurvival signaling during the progression
of diabetic cardiomyopathy and its correction by treatment with BFT.
Methods
Details are provided in the online-only Data Supplement in Expanded Materials and
Methods.
Ethics
Experiments were performed in accordance with the Guide for the Care and Use of
Laboratory Animals (the Institute of Laboratory Animal Resources, 1996) and with approval
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of the British Home Office and the University of Bristol. Type 1 diabetes was induced in
male CD1 mice (Charles River, United Kingdom) by injection of streptozotocin (40 mg/kg
body weight IP per day for 5 days).19 Age-matched animals that received streptozotocin
vehicle served as nondiabetic (healthy) controls. In addition, male obese leptin-receptor
mutant BKS.Cg-+Leprdb/+Leprdb/OlaHsd mice (Harlan, United Kingdom) were used as a
model of insulin-resistant type 2 DM. Increases of blood glucose begin at 4 to 8 weeks in
these mutant mice. Age-matched lean mice (BKS.Cg-m+/+Leprdb/OlaHsd) were used as
control.
Treatment Protocol
The experimental protocols are summarized in supplemental Figure IA and IB. Type 1 DM
mice were randomly assigned to receive BFT (70 mg/kg body weight/day) or vehicle (1
mmol/L HCl) in drinking water starting at 4 weeks from DM induction (last day of
streptozotocin injection) throughout the study. Type 2 DM mice were similarly randomized
to treatments starting from 9 weeks of age. The elected BFT dosage reportedly produces a 4-
fold increase in plasma thiamine.19,20 Gender- and age-matched healthy (for type 1 DM) or
db/+ (for type 2 DM) mice of the same genetic background of the diabetic ones were given
vehicle or BFT and used as reference.
Biochemical Measurements
Confirmation of DM was achieved by measurements of blood glucose levels through the
study (supplemental Figure II). Transketolase, glucose-6-phosphate dehydrogenase, and
GAPDH activities in peripheral blood erythrocytes and left ventricular (LV) tissue were
measured at the time of euthanizing as described previously (n=5 mice per group).16,17,21
AGE levels were measured by ELISA (n=5 mice per group).22
Echocardiography
Dimensional and functional parameters were measured using a high-frequency, high-
resolution echocardiography system. LV chamber dimensions, LV ejection fraction, and LV
fractional shortening were determined as described previously.23
Measurement of LV Pressures and Cardiac Dimensions
LV pressure was measured in anesthetized mice (n=10 to 12 per group) before killing, using
a high-fidelity 1.4F transducer-tipped catheter.
Measurement of Blood Flow
Myocardial blood flow was assessed by the use of fluorescent microspheres, which were
injected into the LV cavity (n=4 to 6 mice per group).24
Immunohistochemistry
Immunohistochemical techniques were used to identify myocardial endothelial cells
(isolectin B4 staining) and smooth muscle cells (α-smooth muscle actin), fibrosis (sirius
red), apoptosis (TUNEL), and hydroxyl radicals (8-hydroxydeoxyguanosine). Superoxides
were revealed using dihydroethidium staining of LV cryostat sections.
In Vitro Studies
Prosurvival Effect of BFT on High Glucose-Challenged Cardiomyocytes—HL-1
cardiomyocytes (a gift from Prof William Claycomb, Louisiana State University Medical
Center, New Orleans, La) were cultured in the presence of high D-glucose (HG, 30 mmol/L)
or normal glucose (5 mmol/L) added with 25 mmol/L D-mannitol as osmotic control. After
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72 hours, cells were supplemented with either BFT (150 μmol/L) or vehicle (1 mmol/L
HCl) for a further 24 hours. Optimal BFT concentration was decided on the basis of pilot
titration studies (supplemental Figure IIIA). In addition, a fixed dosage of BFT was tested to
contrast the apoptotic effect of increasing doses of D-glucose (supplemental Figure IIIB). At
the end of the experiments, cardiomyocytes were collected for measurement of caspase-3/7
activity performed in 6 wells per each condition and repeated 3 times.
Inhibition of PI3K, Akt, or STAT3
To verify the involvement of PI3K/Akt in BFT-induced prosurvival effects, we used either
the PI3K inhibitor LY-294002 (50 μmol/L) or hemagglutinin-tagged dominant negative
mutated form of Akt (Ad.DN-Akt, K179 mol/L) or control Ad.Null (both at 100 multiplicity
of infection). 25 In a separate study, HG-treated HL-1 cardiomyocytes were exposed for 30
minutes to STAT3 inhibitor peptide (Ac-PpYLKTK-OH, 1 mmol/L), a cell permeable
compound that reduces the levels of active STAT3 and inhibits DNA-binding activity of
STAT3 by forming an inactive STAT3-peptide complex.26 This exposure is followed by
treatment with BFT or vehicle. After an additional 24 hours, cells were used for caspase-3/7
activity and Western blot analyses as described earlier. Western blot analyses were
performed in triplicates and repeated 3 times, and caspase-3/7 activity was performed in 6
wells per each condition and repeated 3 times.
Expressional Studies
Western blot analyses were performed on LV samples and HL-1 cardiomyocytes to verify
the effects of DM, HG, and treatment on total and pSTAT3 (Tyr705), protein phosphatase
2A (PP2A), total and pe-nitric-oxide synthase (Ser1177), total and pAkt (Ser473), Pim-1,
total and pBad (Ser112), Bcl-2, total and p-forkhead box O-1 (pFOXO-1), and cleaved
caspase-3 expression.
To assess the O-N-acetylglucosamine (GlcNAc) modification of Akt, LV extracts were
immunoprecipitated with anti-Akt antibody. 27 The precipitate was then immunoblotted
with antibodies for O-GlcNAc (1:10 000, a gift from Prof G.W. Hart, Johns Hopkins
University School of Medicine, Baltimore, Md)28 and for total and pAkt. Akt activity in
protein extracts was measured with a commercial kit.
Quantitative reverse transcription polymerase chain reaction for mouse Pim-1 and 18s rRNA
(for normalization) was performed in a LightCycler. All the expressional analyses were
performed on 4 biological replicates.
Statistical Analysis
Results are presented as mean±SD. The hemodynamic and echocardiographic measurements
were compared by the use of repeated measures 2-way ANOVA (factorial design, 2
independent variables [treatment and presence or absence of diabetes]), followed by
pairwise comparison using the Holm-Sidak method. For the histological, biochemical, and
morphometric analyses, differences between multiple groups were analyzed with 1-way
ANOVA and differences between 2 groups with t test (paired or unpaired as appropriate).
For blood flow and molecular expressional studies, when normality test fails, differences
between groups were analyzed using Siegel-Tukey test. Survival curves were analyzed by
the Kaplan–Meier method, and comparisons were made with the Gehan-Breslow log-rank
test using SigmaStat statistical software. A P<0.05 is considered statistically significant for
all the parameters.
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Results
BFT Attenuates DM-Induced Cardiac Remodeling and Dysfunction
The murine models used in this study showed distinct phases in the evolution of
cardiomyopathy. The initial phase consisted of diastolic dysfunction, as indicated by the
significant decrease in Doppler E/A ratio at 4 weeks from type 1 DM induction (Figure 1A).
A similar figure was observed in 9-week-old type 2 diabetic mice (Figure 2A). BFT partially
rescued the reduced the E/A ratio and prevented the further deterioration of diastolic
function with duration of DM in both diabetic models (Figures 1A and 2A, P<0.01 versus
healthy controls for both comparisons).
The second phase consisted of impaired contractile performance and cardiac dilatation. In
type 1 diabetic mice, systolic function started decreasing from 12 weeks of DM, as indicated
by the progressive reduction in LV ejection fraction and LV fractional shortening (Figure
1B). The late stage was characterized by LV chamber enlargement, LV wall thinning, and
critical fall in cardiac output, which are typical features of heart failure (Figure 1B and
supplemental Figure IVA). Analysis of LV pressure indices and pressure-volume loops
further verified the marked dysfunction of diabetic hearts (Figure 1C). In type 2 diabetic
mice, systolic dysfunction was precocious, being already apparent at 9 weeks of age and
rapidly advancing toward heart failure (Figure 2 and supplemental Figure IVB). Importantly,
BFT treatment resulted in the global improvement of LV performance, pressure indices, and
volumes in both diabetic models (Figures 1 and 2 and supplemental Figure IV, P<0.01
versus vehicle-treated diabetic mice for all parameters) but did not affect cardiac function in
healthy mice (data not shown). Inotropic and lusitropic responses to adrenergic stimulation
were blunted in type 1 diabetic mice (P<0.01 versus healthy controls) but improved by BFT
(P<0.01 versus vehicle-treated diabetic mice, supplemental Figure V).
BFT Improves Survival Rate
The survival rate for type 1 diabetic mice was less than that for healthy controls but was
remarkably improved by BFT (supplemental Figure VI, P<0.001 versus vehicle-treated
diabetic mice).
BFT Improves Myocardial Blood Flow
As shown in Figure 3A, myocardial perfusion was reduced by DM, with this defect being
prevented by BFT in both diabetic models (P<0.01 versus vehicle-treated diabetic mice).
Concordantly, capillary density was reduced in the LV of diabetic mice (P<0.001 versus
healthy controls) and partially conserved by BFT (P<0.01 versus vehicle-treated diabetic
mice, Figure 3B). Fractional analysis of arteriole density revealed a marked decrease in
small (<30 μm diameter) arterioles in the LV of both diabetic models (P<0.001 versus
healthy controls for both comparisons), which was inhibited by BFT (P<0.001 versus
vehicle-treated diabetic mice for both comparisons, Figure 3C).
Histological Validation of BFT Effects
Cardiomyocyte cross-sectional area was reduced in type 1 diabetic mice (66±8 μm2 versus
83±6 μm2 in healthy controls; P<0.01) and preserved by BFT (79±7 μm2; P<0.01 versus
vehicle-treated diabetic mice). BFT remarkably prevented cardiomyocyte apoptosis and
interstitial fibrosis in both diabetic models (Figure 4; P<0.01 for both comparisons).
BFT Activates the Pentose Phosphate Shunt Pathway and Reduces Oxidative Stress
We found that the activity of transketolase, glucose-6-phosphate dehydrogenase, and
GAPDH is reduced in diabetic hearts (Figure 5A through 5C) and associated with marked
Katare et al. Page 5
Circ Heart Fail. Author manuscript; available in PMC 2010 May 10.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
increase in AGE (Figure 5D) and O-GlcNAc protein modification (see later). BFT prevented
these effects and avoided the increase in reactive oxygen species levels in the heart of both
diabetic models (Figure 5E and supplemental Figure VII; P<0.01 versus vehicle-treated
diabetic mice for both comparisons).
BFT Prevents DM-Induced Downregulation of STAT3/Akt/Pim-1
Surprisingly, at initial stages, type 1 diabetic hearts showed increased pAkt and peNOS
levels but low Pim-1 protein (Figure 6) and mRNA expression (supplemental Figure VIIIA).
Importantly, Pim-1 continuously decreased with progression of cardiomyopathy in parallel
with accruing changes in its upstream modulators. In temporal sequence, the first change
consisted of the decrease in the activated form of STAT3 (STAT3-p-Tyr705), which
reportedly induces Pim-1 expression.29 This decrease was followed by an increase in PP2A,
which is known to induce Pim-1 mRNA downregulation and protein degradation (data not
shown).30 At a later stage, when heart failure was overtly manifested, the diabetic
myocardium showed reduced pAkt (Figure 6B) and Akt activity (Figure 6J) and increased
O-GlcNAc modification of Akt, which was previously associated with Akt inhibition
(Figure 6K).31 Levels of peNOS and pFOXO-1 also were decreased in the failing heart of
type 1 diabetic mice (Figure 6C and 6D).
Previous studies showed that both Akt and Pim-1 phosphorylates the proapoptotic Bad,
resulting in the formation of Bad-(14 to 3-3) protein homodimer, which leaves Bcl-XL and
Bcl-2 free to inhibit apoptosis.11,32,33 We found that down-regulation of Akt/Pim-1
signaling by type 1 DM is associated to reduced pBad (Ser 112) and Bcl-2 levels and
increased cleaved caspase-3 (Figure 6G through 6I).
The heart of type 2 diabetic mice exhibited a marked decrease in STAT3/Pim-1 and
modification of Pim-1 downstream effectors but at variance with type 1 DM, also showed an
early reduction in Akt phosphorylation and activity (Figure 7). The global depression of
STAT3/Akt/Pim-1 was mirrored by a more rapid evolution of cardiomyopathy.
Importantly, BFT prevented the downregulation of STAT3 and Pim-1 and the O-GlcNAc
modification of Akt, thereby preserving Akt activity and downstream targets in both diabetic
models (Figures 6 and 7). In contrast, myocardial PP2A levels remained increased in BFT-
treated diabetic mice (data not shown).
Finally, to verify the direct action of BFT on cardiomyocytes, we performed in vitro assays
in which adult cardiomyocytes were cultured in HG or normal glucose in the presence of
BFT or vehicle. Consistent with in vivo experiments, HG increased cardiomyocyte
apoptosis, this effect being prevented by BFT (supplemental Figure IXA). The antiapoptotic
action of BFT was paralleled by conservation of Pim-1 at mRNA (supplemental Figure
VIIIC) and protein level (supplemental Figure IXB) and inhibition of HG-induced effects on
pBad and Bcl-2 (supplemental Figure IXC and IXD). Furthermore, BFT contrasted HG-
induced decreases in pSTAT3 (supplemental Figure IXE), pAkt and Akt activity
(supplemental Figure IXF and IXG) and peNOS and pFOXO-1 (supplemental Figure IXH
and IXI). Of note, HG reduced the nuclear localization of Akt, which is necessary for Akt to
induce Pim-1 expression and phosphorylate or inhibit FOXOs,34 but BFT restored proper
nuclear Akt levels (supplemental Figure IXJ).
Infection of cardiomyocytes with Ad.DN-Akt, verified by assessing the expression of
hemagglutinin tag (data not shown), abrogated the stimulating action of BFT on pAkt
without affecting STAT3. Furthermore, Ad.DN-Akt significantly inhibited the antiapoptotic
action of BFT under HG and contrasted the effects of BFT on Pim-1, pBad, and Bcl-2
(supplemental Figure XA through XF). Prevention of apoptosis by BFT was similarly
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reduced by the PI3K inhibitor LY294002 (supplemental Figure XG). Treatment of
cardiomyocytes with STAT3 inhibitor reduced basal and BFT-stimulated pSTAT3 levels
without affecting pAkt (supplemental Figure XH and XI). STAT3 inhibition potentiated
Pim-1 downregulation and cardiomyocyte apoptosis under HG (supplemental Figure XJ and
XM). It also contrasted BFT in preserving Pim-1 expression and to a lesser extent pBad and
Bcl-2 (supplemental Figure XJ through XL) but was ineffective in inhibiting the
antiapoptotic action of BFT, suggesting that pAkt induction by BFT could compensate for
STAT3/Pim-1 deficit to support cardiomyocyte viability under HG conditions.
Discussion
In a previous report in streptozotocin mice, a 2-week administration of BFT preserved in
vitro contractile properties and intracellular Ca2+ kinetics of cardiomyocytes.35 To the best
of our knowledge, however, this is the first study to show the therapeutic potential of long-
term treatment with BFT for prevention of cardiomyopathy in models of types 1 and 2 DM,
which is particularly relevant in light of the prevalent incidence of cardiomyopathy in
patients with type 2 DM. The effect of BFT was documented by echocardiography follow-
up of LV function, Millar transducer measurement of LV pressure, and cardiac
morphometry. Furthermore, we newly reported that BFT prevents myocardial microvascular
rarefaction, thereby improving myocardial perfusion of diabetic hearts. The role of
microcirculation in the pathogenesis of diabetic cardiomyopathy has been highlighted by a
study in which gene therapy with vascular endothelial growth factor-A prevented capillary
rarefaction and cardiac dysfunction in mice.36 Our in vitro studies, however, indicate a
direct action of BFT on cardiomyocyte survival; thus, the improved myocardial blood flow
might additively contribute to preservation of cell viability and cardiac performance.
Another novel contribution of this study is the first documentation of chronologic alterations
in components of prosurvival signaling during progression of cardiomyopathy and of the
impact of BFT on these molecular changes. Our results of reduced myocardial pAkt levels in
failing diabetic hearts are consistent with earlier reports in mice with long-standing DM,
37,38 yet the mechanism responsible for Akt inhibition was not clear. Emerging evidence
indicates that HG-induced activation of hexosamine pathway plays a role in the etiology of
diabetic cardiomyopathy through O-GlcNAc modification of transcription factors and
proteins involved in cardiomyocyte function.39 We show for the first time the combination
of reduced Akt activity and increased O-GlcNAc modification of Akt in myocardium of
diabetic mice. Inactivation of Akt may account for increased cardiomyocyte apoptosis in
failing diabetic hearts because Akt directly controls the phosphorylation and sequestration of
the Bad and FOXO transcription factors.40 Of note, BFT, which reportedly reduces the
glucose flux to the hexosamine pathway,17 abrogated DM-induced O-GlcNAc modification
of Akt, thereby restoring Akt activity and Bad and FOXO-1 phosphorylation levels.
One intriguing aspect of our results consists of increased Akt activity at early stages of
cardiomyopathy in type 1 diabetic mice, which is possibly a compensatory attempt to
combat DM-induced damage. On the other hand, chronic Akt activation could have
detrimental effects on the heart through inhibition of insulin receptor substrate/PI3K
signaling and disruption of the coordinated association between adaptive cardiac
hypertrophy and microvascular growth.41,42 Of note, while confirming the reduction of
microvascular density in failing diabetic hearts, our data show no evidence of hypertrophic
remodeling during initial increase of Akt in type 1 diabetic hearts. The time duration of Akt
activation might have been too short to sustain LV hypertrophy in our experimental setting.
Furthermore, the dual action of Akt on cardiomyocyte survival and growth could depend on
the specific intracellular location of activated Akt.10
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Many of the cardiac actions of Akt are ascribed to be Pim-1 dependent. For instance, Akt
activation induces Pim-1 expression, but forced expression of Akt failed to protect the
infarcted myocardium of Pim-1-deficient mice.11 Pim-1-induced cardioprotection is
reportedly mediated by upregulation of Bcl-2 and Bcl-XL as well as phosphorylation and
inactivation of Bad. Our in vitro findings showing that PI3K/Akt inhibition abrogates the
action of BFT on cardiomyocyte survival under HG and contrasts the stimulatory effect of
BFT on Pim-1 and Bcl-2 indicate that Akt is a crucial facet of cardioprotection exerted by
this compound. This concept is reinforced by the finding that BFT-induced Akt upregulation
in HG-challenged cardiomyocytes is sufficient for the prevention of apoptosis under STAT3
inhibition.
Our in vivo findings in type 1 diabetic mice showed, however, a situation more intricate than
predicted in vitro. In the compensated phase, changes in myocardial pAkt and Pim-1 levels
were not synchronous, with Pim-1 starting to decrease earlier than pAkt. This pattern might
suggest a crucial role of Pim-1 in early diastolic dysfunction and indicate the contribution of
mechanisms independent of Akt in Pim-1 downregulation. One possible candidate is
STAT3, which upregulates Pim-1 expression by binding with its promoter.43 In line, we
found that pSTAT3 is reduced at compensated stages of diabetic cardiomyopathy. In
addition, DM induced the expression of PP2A, which is known to dephosphorylate and
inactivate Pim-1.30 An additional explanation for the apparent discrepancy between high
pAkt and low Pim-1 levels at the early stage of cardiomyopathy is that pAkt might remain
sequestered in the cytosol and thus unable to upregulate Pim-1 expression. This is in line
with the reduced nuclear localization of Akt in HG-challenged cardiomyocytes. Of note,
BFT prevented the reduction in pSTAT3 and preserved nuclear Akt but failed to decrease
PP2A. Thus, the action of BFT seemingly affects positive regulators of Pim-1 rather than
mechanisms of Pim-1 destabilization.
The protective action of BFT extends to other mechanisms implicated in the pathogenesis of
diabetic cardiomyopathy. Hyperglycemia causes oxidative stress by inducing reactive
oxygen species and dampening antioxidant generation. In this study, we newly showed that
BFT reduces superoxide and hydroxyl radical levels in diabetic hearts by inducing the
activation of pentose phosphate pathway, which regenerates the antioxidant NADPH.
Furthermore, superoxide overproduction by hyperglycemia inhibits the glycolytic enzyme
GAPDH,17 thereby diverting metabolites from glycolysis into major pathways of
hyperglycemic damage.20 Importantly, we showed that these effects of DM were inhibited
by BFT as evidenced by increased GAPDH activity and reduced AGE levels. Prevention of
AGE accumulation could account for inhibition of interstitial fibrosis by BFT.
In conclusion, our results illustrate fundamental mechanisms that are involved in the
pathogenesis of diabetic cardiomyopathy and could be prevented by BFT (summarized in
supplemental Figure XI). Implications of the present preclinical study to the clinical field
should be evaluated cautiously in the light of similarities and differences of cardiomyopathy
developing in patients with diabetes and diabetic animal models. Furthermore, the dosage
and time schedule of BFT supplementation represent a crucial issue, as for other preventive
treatments, that sustained activation of proto-oncogenes, such as Akt and Pim-1, might
increase the risk of cancer. This concern, however, is not supported by our results showing
no evidence of adverse effects but. Rather. improved survival of diabetic mice treated with a
high dose of BFT.
CLINICAL PERSPECTIVE
Diabetes mellitus is a potent and prevalent risk factor for heart failure, independently of
coronary artery disease or hypertension. Importantly, diabetes mellitus can affect cardiac
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structure and function independently of coexisting hypertension or ischemic heart
disease, resulting in a condition named diabetic cardiomyopathy. Diabetic
cardiomyopathy has an insidious onset, manifesting with isolated diastolic dysfunction,
which progresses with time to global heart failure. The present study unravels distinct
molecular signatures of the progression of diabetic cardiomyopathy from early and
probably reversible stages to more advanced heart remodeling and dilatation. In
particular, we clarified a possible link between the metabolic disorder and epigenetic
changes that make the prosurvival Akt/Pim1 duo dysfunctional, thereby compromising
the heart's performance. This discovery opens new windows of therapeutic opportunity to
combat this increasingly harmful complication of diabetes. Importantly, vitamin B1
analogue benfotiamine is able to beneficially interfere with the Akt/Pim1 disturbed
signaling and thus prevents the mismatch between angiogenesis and cardiomyocyte
remodeling in the diabetic heart. Whether benfotiamine is therapeutically useful needs
now to be demonstrated by clinical trials. Furthermore, because the main action of
benfotiamine is to boost the activity of transketolase, a key enzyme of the pentose
phosphate pathway, and because transketolase activity is reduced in diabetes, it is
important to determine whether patients with reduced transketolase activity are
susceptible to develop an accelerated form of cardiomyopathy. If this is proved true,
patients with low transketolase would become the best candidates to benfotiamine
treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
BFT prevents ventricular dysfunction in type 1 DM. A, Representative pulsed Doppler
images and table showing the effect of BFT on E/A ratio. E and A waves represent mitral
valve velocity during early diastolic filling and atrial contraction, respectively (n=16 mice
per group). B, Indexes of LV function assessed by echocardiography (n=16 per group). C (i–
iii), Bar graphs showing the effect of BFT on LV end-diastolic pressure (LVEDP), LV end-
systolic pressure (LVESP), and maximum and minimum rates of developed pressure (dP/dt)
at 16 weeks of treatment (n=12 per group). C (iv), Representative pressure-volume (PV)
loops obtained by integrated measurement of LV pressure (Millar catheter) and volume
(echocardiography). Values are mean±SD. BFT did not affect cardiac function in healthy
mice (data not shown). STZ indicates streptozotocin. Results of pairwise comparison are as
follows: *P<0.01 and **P<0.01 versus healthy controls; #P<0.01 and ##P<0.01 versus
vehicle-treated diabetic mice.
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Figure 2.
BFT prevents ventricular dysfunction in type 2 DM. A, Representative images and table
showing the effect of BFT on Doppler E/A ratio (n=10 per group). B, Echocardiography
indices of LV function (n=10 per group). C (i–iii), Bar graphs showing the effect of BFT on
LV pressure and volume indices at 8 weeks of treatment (n=10 per group). C (iv),
Representative pressure-volume loops. Values are mean±SD. BFT did not affect cardiac
function in db/+ mice (data not shown). LVEDP indicates LV end-diastolic pressure;
LVESP, LV end-systolic pressure; dP/dt, maximum and minimum rates of developed
pressure; and PV, pressure-volume. Results of pairwise comparison are as follows: *P<0.01,
**P<0.001, and ***P<0.0001 versus db/+ mice; #P<0.01, ##P<0.001, and ###P<0.0001
versus vehicle-treated db/db mice.
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Figure 3.
BFT improves myocardial blood flow and vascularization. A, Bar graphs showing the effect
of BFT on myocardial blood flow in type 1 (n=6 per group, 16-week treatment) and type 2
diabetic mice (n=4 per group, 8-week treatment). Age-matched untreated healthy controls
for the 2 diabetic groups are shown for comparison (n=4 to 6 mice). B, Representative
immunohistochemistry images of microvasculature and bar graphs showing LV capillary
density of diabetic mice (n=6, treatment duration as above). C, Representative
immunohistochemistry images of microvasculature and bar graphs showing LV arteriole
density of diabetic mice (n=6 per group, treatment duration as above). Age-matched
untreated healthy controls for type 1 DM and db/+ for type 2 DM groups are shown for
comparison (n=6). Scale bars are 50 μm. Results of pairwise comparison are as follows:
*P<0.01 and **P<0.001 versus healthy controls in type 1 DM or db/+ mice in type 2 DM;
#P<0.01 and ##P<0.001 versus vehicle-treated diabetic mice in type 1 DM or db/db mice in
type 2 DM.
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Figure 4.
BFT prevents cardiomyocyte apoptosis and cardiac fibrosis. A and B, Representative
microphotographs and bar graphs showing the effect of BFT on cardiomyocyte apoptosis
and interstitial fibrosis (n=5 per group). Scale bars are 50 μm. Treatment duration and
statistical analysis as in Figure 3. *P<0.01 and **P<0.001 versus healthy controls in type 1
DM or db/+ mice in type 2 DM; #P<0.01 versus vehicle-treated diabetic mice in type 1 DM
or db/db mice in type 2 DM.
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Figure 5.
BFT activates the pentose phosphate pathway and inhibits reactive oxygen species. Bar
graphs showing the effect of BFT on transketolase (A), glucose-6-phosphate dehydrogenase
(G6PD) (B), GADPH (C), and AGE (D) (n=5 per group, each assay in triplicate).
Representative microphotographs and bar graphs showing myocardial hydroxyl radical
levels (E) (n=5 per group). Treatment duration and statistical analysis as in Figure 3. 8-
OHDG indicates 8-hydroxydeoxyguanosine. *P<0.01, **P<0.001, and ***P<0.0001 versus
healthy controls in type 1 DM or db/+ mice in type 2 DM; #P<0.001, ##P<0.001, and
###P<0.01 versus vehicle-treated diabetic mice in type 1 DM or db/db mice in type 2 DM.
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Figure 6.
BFT stimulates prosurvival signaling in type 1 DM. Representative blots (A) and bar graphs
(B through I) showing the levels of pAkt, peNOS, pFOXO-1, pSTAT3, Pim-1, pBad, Bcl-2,
and cleaved caspase-3 (n=4 per group). Bar graphs showing myocardial Akt activity (J).
Representative immunoblots and bar graphs showing O-GlcNAc modification of Akt in
diabetic hearts (K) (n=4 per group). Values are expressed as n-fold changes toward age-
matched healthy controls. STZ indicates streptozotocin. Siegel-Tukey test detected statistical
differences as follows: *P<0.01 and **P<0.001 versus healthy controls; #P<0.01 and
##P<0.001 versus vehicle-treated diabetic mice.
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Figure 7.
BFT stimulates prosurvival signaling in type 2 DM. Representative blots (A) and bar graphs
(B through I) showing the levels of pAkt, peNOS, pFOXO-1, pSTAT3, Pim-1, pBad, Bcl-2,
and cleaved caspase-3 (n=4 per group). Bar graphs showing myocardial Akt activity (J).
Representative immunoblots and bar graphs showing O-GlcNAc modification of Akt in
diabetic hearts (K) (n=4 per group). Values are expressed as n-fold changes toward age-
matched healthy controls. Siegel-Tukey test detected statistical differences are as follows:
*P<0.01, **P<0.001, and ***P<0.001 versus db/+ mice; #P<0.01 and ##P<0.001 versus
vehicle-treated db/db mice.
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